Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer.
The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.
TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of TexasM. D.
Anderson Cancer Center.
The company was incorporated in 2016 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 18, 24 | -5.28 Decreased by -214.29% | -16.17 Increased by +67.35% |
| Aug 16, 24 | -976.80 Decreased by -29.59 K% | -765.60 Decreased by -27.59% |
| Apr 1, 24 | -22.84 Decreased by -5.91 K% | -10.80 Decreased by -111.48% |
| Mar 29, 24 | -627.33 Decreased by -156.73 K% | -356.40 Decreased by -76.02% |
| Nov 13, 23 | -1.68 Decreased by -409.09% | -1.50 Decreased by -12.00% |
| Aug 14, 23 | -3.29 Decreased by -813.89% | -3.39 Increased by +2.95% |
| May 15, 23 | -0.38 Decreased by -72.73% | -0.38 |
| Mar 31, 23 | -0.40 Decreased by -73.91% | -0.38 Decreased by -5.26% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.32 M Increased by +56.20% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -5.19 M Decreased by -19.56% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 753.15 K Increased by +N/A% | -3.33 M Increased by +30.87% | Decreased by -441.72% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -4.09 M Increased by +77.80% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.30 M Decreased by -23.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -4.34 M Increased by +6.33% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -4.81 M Decreased by -38.97% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -18.41 M Decreased by -108.38% | Decreased by N/A% Decreased by N/A% |